J&J Wants to Own Every Line of Myeloma Treatment. It Might Be Working.
J&J's Talvey-Darzalex combo cut the risk of myeloma progression or death by up to 72% in a pivotal phase 3 trial presented at EHA 2026. The data cements J&J's strategy of stacking novel bispecifics onto its blockbuster Darzalex backbone, and the competition may already be a step behind.
Imagine a company that sells you the lock, the key, and the security system. That's Johnson & Johnson's play in multiple myeloma right now. And the data they just dropped at the European Hematology Association (EHA) meeting suggests the strategy is paying off in a big way.
The headline: J&J's combination of Talvey (talquetamab) and Darzalex (daratumumab) cut the risk of disease progression or death by up to 72% compared to the current standard of care in patients whose myeloma had come back after at least one prior treatment. That's not a marginal improvement. That's a paradigm shift knocking on the door.
The Trial That Earned a Plenary Slot
The data came from MonumenTAL-3, a phase 3 randomized trial that pitted two Talvey-based regimens against a widely used standard: Darzalex plus pomalidomide plus dexamethasone (called DPd for short). One arm added Talvey to Darzalex alone (Tal-D). The other added Talvey to Darzalex and pomalidomide (Tal-DP).
Both experimental arms crushed the control.
The Tal-DP combo reduced the risk of progression or death by 72% (hazard ratio 0.28). Tal-D wasn't far behind, at a 67% risk reduction (hazard ratio 0.33). Both hit statistical significance with p-values below 0.0001, the kind of results that make statisticians do a double-take.
At the two-year mark, 81.3% of patients on Tal-DP were still progression-free, compared to just 51.2% on the standard regimen. Even more striking: the combo kept more patients alive, with 24-month overall survival reaching 89.2% versus 79.1% for the control. That translates to a 53% reduction in the risk of death.
This is the first phase 3 study to show that a GPRC5D bispecific combination (more on what that means in a second) can beat standard care in earlier-line myeloma. EHA gave it a plenary slot, which is the conference equivalent of a standing ovation before you even start talking.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A Quick Decoder Ring
Let's unpack the science, because the mechanism here is actually pretty elegant.
Talvey is a bispecific antibody, which means it's engineered to grab onto two things at once. One arm latches onto GPRC5D, a protein found on the surface of myeloma cells. The other arm grabs CD3 on T cells (your immune system's assassins). By physically bridging the two, Talvey essentially shoves a T cell face-to-face with a cancer cell and says, "Handle this." The T cell obliges by punching holes in the tumor cell and destroying it.
Darzalex works differently. It's an anti-CD38 antibody that tags myeloma cells for destruction through a separate set of immune mechanisms. Think of it like calling in both the snipers and the artillery; two different weapons hitting two different targets on the same enemy.
That dual-target approach is likely why the responses are so deep and durable. It's much harder for cancer to escape when it's being hunted by two independent systems.
The Side Effect Trade-Off
No free lunch, of course. Talvey comes with a signature set of side effects tied to where GPRC5D shows up in the body (hint: not just on cancer cells). The protein also lives in skin, nails, and taste buds, which means patients often experience skin rashes, nail changes, and altered taste (dysgeusia). In earlier studies, skin-related events hit roughly 65-70% of patients, and taste disturbance affected around 57-63%.
There's also cytokine release syndrome (CRS), the inflammatory flare-up that comes with revving up T cells. It showed up in about 70-80% of patients in earlier-phase data, but was overwhelmingly low-grade and manageable with standard protocols.
The good news from MonumenTAL-3: safety looked consistent with what was already known from each drug individually. Critically, J&J reported that the Tal-D arm actually had a lower rate of severe infections than the standard-of-care control. No new safety signals emerged. For a combination regimen in cancer, that's a genuinely encouraging finding.
J&J's Grand Myeloma Chess Game
Zoom out, and MonumenTAL-3 is really just one move in a much larger strategy. J&J doesn't just want to treat your myeloma at one stage. They want to treat it at every stage.
The company's myeloma portfolio now spans four distinct mechanisms: Darzalex (anti-CD38 antibody), Tecvayli (a BCMA-targeted bispecific), Talvey (GPRC5D bispecific), and Carvykti (BCMA CAR-T cell therapy, with Legend Biotech). That's an unprecedented level of vertical integration in a single cancer type.
Darzalex is already embedded in frontline treatment, and J&J's CEO Joaquin Duato has stated the goal is for "the vast majority of newly diagnosed multiple myeloma patients" to be on a J&J regimen. In Q1 2026, Darzalex sales grew 22.5% year-over-year, while J&J's newly launched oncology agents (including Talvey) collectively generated about $1.2 billion in the quarter.
The company is targeting roughly $25 billion in myeloma revenue by 2030, with Darzalex representing over half. Bispecific combinations like Talvey + Darzalex and Tecvayli + Darzalex are the engines designed to get them there.
The Competition Is Real, But Late
J&J isn't operating in a vacuum. The BCMA bispecific space is getting crowded: Pfizer's Elrexfio (elranatamab) and Regeneron's Lynozyfic (linvoseltamab) are both approved in later-line myeloma. AbbVie has ABBV-383 (etentamig) in late-stage development. Bristol Myers Squibb is pushing its Abecma CAR-T therapy into earlier treatment lines.
But most of these competitors are still fighting over heavily pretreated patients (fourth line and beyond). J&J, with MonumenTAL-3, just planted its flag in second-line territory with randomized phase 3 evidence of superiority. That's a meaningful head start.
Analysts have described the BCMA bispecific market as "saturated," which makes Talvey's GPRC5D target a strategic differentiator. It gives J&J an option for patients who've already been exposed to BCMA-directed therapies, essentially covering the escape routes that cancer might take.
What Happens Next
J&J is already working with regulators globally on the Talvey + Darzalex combination in earlier-line myeloma. If approved, it would give oncologists a potent new option as early as first relapse, potentially reshaping how the entire treatment sequence is constructed.
The investigators behind MonumenTAL-3 didn't mince words: the data "supports a new standard of care" as early as second-line treatment.
For J&J, the math is straightforward. Every line of therapy they dominate is another revenue stream that compounds. With Darzalex as the backbone, bispecifics as the muscle, and CAR-T as the closer, they're building something that looks less like a drug portfolio and more like an ecosystem.
The question isn't whether J&J will be a major force in myeloma through 2030. It's whether anyone else can catch up.
Clinical & Regulatory
5 min read
Prostate Cancer Just Got Its HER2 Moment
The FDA just approved the first targeted therapy for a specific genetic subtype of prostate cancer, turning PTEN loss from a bad prognosis into an actionable target. It's the same precision oncology playbook that transformed breast cancer, and it could reshape how we treat the most common male cancer.
